chartexchange

TGTX
TG Therapeutics, Inc.
stockNASDAQ

Market OpenNov 16, 2026 10:39:10 AM EST
63.61USD-1.395%(-0.90)255,078
Pre-marketNov 16, 2026 9:23:30 AM EST
64.84USD+0.510%(+0.33)
55.24Bid63.67Ask8.43Spread
Loading…
Loading…
Healthcare
Biotechnology
CEO
Michael Weiss
HQ
Morrisville, NC, USA
Previous Close
$64.49
Beta
0.68
52-Week High
$68.03 2026-11-10
52-Week Low
$26.76 2026-03-12
SMA 50
$56.69
SMA 200
$45.38
Avg. Vol 10D
2.66M
Avg. Vol 30D
1.91M
Avg. Vol 90D
1.99M
Relative Vol
0.13
151.15M
133.57M
28,765,675
0.2500%
1,300,000
Mar 1, 2027 (105d)
Apr 30, 2012 · 1-for-56.243 (reverse)
TGTX Profile

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".

TGTX Performance
PeriodPriceDateChangeBeta
1W63.382026-11-09+0.38%1.480
1M53.972026-10-16+17.88%1.098
3M49.282026-08-17+29.10%0.951
6M39.502026-05-15+61.06%0.320
1Y30.692025-11-17+107.30%0.677
2Y29.542024-11-15+115.37%—
5Y26.642021-11-16+138.81%1.750
TGTX Stock Summary

TG Therapeutics, Inc. (NASDAQ:TGTX) stock price today is $63.62, and today's volume is 248,529. TGTX is down 1.380% today. The 30 day average volume is 1.91M. TGTX market cap is $9.62B with 151.15M shares outstanding.